Multivalent OspA polypeptides and methods and uses relating thereto
AssigneeValneva Austria GmbH
InventorsUrban Lundberg, Andreas Meinke, Abhijeet Nayak, Wolfgang Schüler
Life of this patent
Estimating the term…
Abstract
The present invention relates to an immunogenic polypeptide, a nucleic acid encoding the same, a pharmaceutical composition comprising the same and the immunogenic polypeptide, nucleic acid or pharmaceutical composition for use as a medicament, particularly a vaccine, or for use in a method of treating or preventing a Borrelia infection.
Claims20
A nucleic acid molecule encoding an immunogenic polypeptide comprising a C-terminal domain of an outer surface protein A (OspA) of Borrelia, characterized in that said C-terminal OspA domain comprises at least three specific OspA epitopes each from distinct Borrelia strains causing Lyme Borreliosis;
- wherein said C-terminal OspA domain is able to induce a protective immune response to all of said distinct Borrelia strains, wherein the C-terminal OspA domain is selected from the group consisting of SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 12, SEQ ID NO:
- 13, and immunogenic variants thereof that have at least 95% sequence identity with any one of SEQ ID NO:9, SEQ ID NO:
- 10, SEQ ID NO:
- 12, or SEQ ID NO:
- 13, and wherein a three-dimensional structure of the C-terminal OspA domain is stabilized by introduction of at least two cysteine residues that form a disulfide bond.
Dependencies are inferred from the claim text.